Skip to main content

Advertisement

Table 4 Experimental factors associated with difference to be detected regarding death or recurrence of an unnamed cancer presented as an absolute risk difference and as odds ratios

From: How do researchers determine the difference to be detected in superiority trials? Results of a survey from a panel of researchers

  Difference to be detected Difference to be detected expressed as odds ratio
Factors tested Mean reduction in death or cancer recurrencea, % (95 % CI) P-value Mean odds ratio (95 % CI) P-value
Baseline risk   <0.001   0.930
 Low risk (10 % of mortality/recurrence) (n = 183)
 High risk (60 % of mortality/recurrence) (n = 170)
3.2 (2.4–4.0)
11.2 (10.3–12.0)
0.230 0.64 (0.61–0.67)
0.63 (0.60–0.66)
Primary outcome     0.322
 Mortality (n = 174)
 Recurrence rate (n = 179)
6.7 (5.9–7.5)
7.4 (6.6–8.2)
0.649 0.65 (0.62–0.68)
0.62 (0.60–0.65)
Disadvantages of the new treatment     0.206
 Higher cost mentioned (n = 180)
 Higher cost not mentioned (n = 173)
7.2 (6.4–8.0)
6.9 (6.1–7.7)
0.005 0.62 (0.59–0.65)
0.65 (0.62–0.68)
Study population     0.031
 Adults aged <50 years (n = 180)
 Adults aged >75 years (n = 173)
7.9 (7.1–8.7)
6.2 (5.4–7.0)
  0.61 (0.59–0.64)
0.66 (0.63–0.69)
  1. 95 % CI 95 % confidence interval
  2. aMarginal means from the multivariable linear regression model